Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

This trial offers CAR-T cell therapy targeting CD19 — a protein found on certain blood cancer cells — for people with relapsed or treatment-resistant B-cell blood cancers, including certain types of leukemia and lymphoma. The therapy uses your own immune cells, re-engineered to attack the cancer. **You may be eligible if...** - You have relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (ALL), B-cell lymphoma, or CLL/SLL - For ALL: You are between 0 and 60 years old, in first or subsequent relapse, or have persistent measurable residual disease - You are in reasonably good functional health (ECOG ≤2 for adults, Lansky >50 for children) - Females of childbearing age must have a negative pregnancy test **You may NOT be eligible if...** - Your cancer does not express the CD19 protein - You have uncontrolled serious organ problems - You are pregnant or breastfeeding - You have active uncontrolled infections Talk to your doctor to see if this trial is right for you.